Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
filingDate |
2001-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e09c7a9af5bad956d0aeaf7d4f7d6e70 |
publicationDate |
2003-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1272035-A1 |
titleOfInvention |
Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
abstract |
A kappa opioid blocking agent is used for optimizing dopamine homeostasis during administration of opioid analgesics, for preventing mortal respiratory depression due to drug overdose, and for dissuading a human or animal from self-administering excessive amounts the opioid analgesic. |
priorityDate |
2000-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |